Insights

Innovative Diagnostics Hepion Pharmaceuticals develops first-in-class liquid biopsy tests with high sensitivity and specificity for early hepatocellular carcinoma detection, presenting significant opportunities for partnerships with oncology clinics and diagnostic labs seeking advanced screening tools.

Market Expansion With the liquid biopsy market projected to reach nearly nine billion dollars in the US by 2035, there is substantial growth potential for Hepion’s diagnostic solutions, enabling sales efforts targeting high-risk patient populations and healthcare providers prioritizing early cancer detection.

Strategic Collaborations Hepion’s recent licensing agreements and partnerships with diagnostics firms like Cirna Diagnostics and New Day Diagnostics indicate readiness for joint ventures and co-marketing arrangements with companies looking to augment their oncology and liver disease diagnostic portfolios.

Theranostics Potential The company’s integrated approach to combining diagnostics and therapeutics offers avenues for value creation through collaborations with pharmaceutical and biotech firms focusing on innovative cancer treatment and monitoring solutions.

Emerging Leadership Recent leadership transitions, including the appointment of an interim CEO, suggest opportunities for engagement with executive decision-makers and strategic investors interested in supporting companies with breakthrough liquid biopsy technologies.

Hepion Pharmaceuticals Tech Stack

Hepion Pharmaceuticals uses 8 technology products and services including Cloudflare, RSS, Font Awesome, and more. Explore Hepion Pharmaceuticals's tech stack below.

  • Cloudflare
    Content Management System
  • RSS
    Content Management System
  • Font Awesome
    Font Scripts
  • amCharts
    Javascript Graphics
  • Google Maps
    Maps
  • DocuSign
    Miscellaneous
  • Piwik
    System Analytics & Monitoring
  • HTTP/3
    Web & Portal Technology

Media & News

Hepion Pharmaceuticals's Email Address Formats

Hepion Pharmaceuticals uses at least 1 format(s):
Hepion Pharmaceuticals Email FormatsExamplePercentage
FLast@hepionpharma.comJDoe@hepionpharma.com
49%
First.Last@hepionpharma.comJohn.Doe@hepionpharma.com
1%
FMiddleLast@hepionpharma.comJMichaelDoe@hepionpharma.com
1%
FLast@hepionpharma.comJDoe@hepionpharma.com
49%

Frequently Asked Questions

Where is Hepion Pharmaceuticals's headquarters located?

Minus sign iconPlus sign icon
Hepion Pharmaceuticals's main headquarters is located at Edison, New Jersey 08837 United States. The company has employees across 2 continents, including North AmericaEurope.

What is Hepion Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Hepion Pharmaceuticals's official website is hepionpharma.com and has social profiles on LinkedIn.

What is Hepion Pharmaceuticals's SIC code NAICS code?

Minus sign iconPlus sign icon
Hepion Pharmaceuticals's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Hepion Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of March 2026, Hepion Pharmaceuticals has approximately 4 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer & Board Director: K. L.Chief Executive Officer: R. F.Svp Clinical Pharmacology: P. M.. Explore Hepion Pharmaceuticals's employee directory with LeadIQ.

What industry does Hepion Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Hepion Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Hepion Pharmaceuticals use?

Minus sign iconPlus sign icon
Hepion Pharmaceuticals's tech stack includes CloudflareRSSFont AwesomeamChartsGoogle MapsDocuSignPiwikHTTP/3.

What is Hepion Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Hepion Pharmaceuticals's email format typically follows the pattern of FLast@hepionpharma.com. Find more Hepion Pharmaceuticals email formats with LeadIQ.

Hepion Pharmaceuticals

Biotechnology ResearchNew Jersey, United States2-10 Employees

Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) is pioneering early cancer detection with novel liquid biopsy diagnostics, on a path toward integrating diagnostics and therapeutics in a closed loop theranostics model. The company is developing first-in-class liquid biopsy tests for hepatocellular carcinoma (HCC) in high-risk patients, with potential applications across other solid tumors.  

Hepion holds global commercialization rights to two genomic-based liquid biopsy tests, each demonstrating unprecedented sensitivity and specificity in detecting liver cancer in high-risk cirrhotic patients in clinical trials. The company’s Methylated Septin9 (mSEPT9) is a validated biomarker for HCC detection and surveillance, backed by strong clinical evidence, established IP, and a prospective clinical development plan. It has the unique ability to delineate between very early (Barcelona Clinic Liver Cancer [BCLC] stage A1) and early-stage HCC (BCLC stages A2, A3, and A4) – a key differentiator from other diagnostic tests. Its other asset, a circulating tumor RNA (ctRNA) platform that detects HCC-specific mutant RNA variants in blood, represents a next-generation approach to liquid biopsy. The ctRNA asset is in-licensed from Cirna Diagnostics, a spinout company out of the Baruch S. Blumberg Institute (BSBI). 

Liver cancer is the fastest growing and fifth deadliest cancer in the United States and the third deadliest cancer globally. Early HCC is asymptomatic, making screening high-risk patients critical, yet the current standard of care misses up to 75% of cases.  The global liquid biopsy market is currently valued at $10 billion and growing, and in the U.S. alone is projected to reach nearly $9 billion by 2035. Hepion's flexible business models, strong IP position, and public company structure create multiple pathways to value creation for partners ready to make a real impact in oncology.

Section iconCompany Overview

Headquarters
Edison, New Jersey 08837 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $1M$10M

    Hepion Pharmaceuticals's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Hepion Pharmaceuticals's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.